Interleukin-6 as a therapeutic target in candidate inflammatory diseases

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 483-487

  Nishimoto, N ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALD 518; AMYLOID A PROTEIN; BE 8; C REACTIVE PROTEIN; CHOLESTEROL; CNTO 136; CNTO 328; INTERLEUKIN 6; METHOTREXATE; REGN 88; TOCILIZUMAB; UNCLASSIFIED DRUG;

AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; AORTA ARCH SYNDROME; CACHEXIA; CHOLESTEROL BLOOD LEVEL; CINCA SYNDROME; CLINICAL TRIAL; COLON CROHN DISEASE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GLOMERULONEPHRITIS; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY CARCINOMA; LYMPHOMA; MESOTHELIOMA; MONOTHERAPY; MUCKLE WELLS SYNDROME; MULTIPLE MYELOMA; MYELOMA CELL; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; INFLAMMATION; INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 77949875590     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.313     Document Type: Review

References (37)

1. Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324, 73-76 (1986).
2. Kishimoto, T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu. Rev. Immunol. 23, 1-21 (2005).
3. Mima, T. & Nishimoto, N. Clinical value of blocking IL-6 receptor. Curr. Opin. Rheumatol. 21, 224-230 (2009).
4. Dong, C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat. Rev. Immunol. 8, 337-348 (2008).
5. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic efector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
6. Wendling, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J. Rheumatol. 20, 259-262 (1993).
7. Choy, E.H. et al. Therapeutic beneft of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 46, 3143-3150 (2002).
8. Nishimoto, N. et al. Toxicity, pharmacokinetics, and dose-fnding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30, 1426-1435 (2003).
9. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 50, 1761-1769 (2004).
10. Maini, R.N. et al.; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817-2829 (2006).
11. Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic beneft from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162-1167 (2007).
12. Smolen, J.S. et al.; OPTION Investigators. Efect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987-997 (2008).
13. Genovese, M.C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968-2980 (2008).
14. Nishimoto, N. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): signifcant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod. Rheumatol. 19, 12-19 (2009).
15. Nishimoto, N., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T. & Azuma, J. Long-term safety and efcacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efcacy in a 5-year extension study. Ann. Rheum. Dis. 68, 1580-1584 (2009).
16. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67, 1516-1523 (2008).
17. De Benedetti, F. Targeting interleukin-6 in pediatric rheumatic diseases. Curr. Opin. Rheumatol. 21, 533-537 (2009).
18. Yokota, S. et al. Therapeutic efcacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52, 818-825 (2005).
19. Yokota, S. et al. Efcacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371, 998-1006 (2008).
20. Iwamoto, M., Nara, H., Hirata, D., Minota, S., Nishimoto, N. & Yoshizaki, K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 46, 3388-3389 (2002).
21. Nakahara, H., Mima, T., Yoshio-Hoshino, N., Matsushita, M., Hashimoto, J. & Nishimoto, N. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod. Rheumatol. 19, 69-72 (2009).
22. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-96; discussion, 947 (2004).
23. Nishimoto, N., Nakahara, H., Yoshio-Hoshino, N. & Mima, T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum. 58, 1197-1200 (2008).
24. Matsubara, T. et al. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. Arthritis Rheum. 54, 2314-2320 (2006).
25. Beck, J.T. et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N. Engl. J. Med. 330, 602-605 (1994).
26. Nishimoto, N. et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95, 56-61 (2000).
27. Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106, 2627-2632 (2005).
28. Bataille, R. et al. Biologic efects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86, 685-691 (1995).
29. van Zaranen, H. et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J. Clin. Invest. 98, 1441-1448 (1996).
30. van Zaranen, H. et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 102, 783-790 (1998).
31. Moreau, P., Harousseau, J.L., Wijdenes, J., Morineau, N., Milpied, N. & Bataille, R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol. 109, 661-664 (2000).
32. Okuda, Y. & Takasugi, K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 54, 2997-3000 (2006).
33. Nishida, M. et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann. Rheum. Dis. 68, 1235-1236 (2009).
34. Kawai, M. et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology. (Oxford). 48, 318-319 (2009).
35. Klein, B. et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78, 1198-1204 (1991).
36. Emilie, D. et al. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodefciency syndrome and lymphoma: efect on lymphoma growth and on B clinical symptoms. Blood 84, 2472-2479 (1994).
37. Blay, J.Y. et al. Role of interleukin-6 in the paraneoplastic infammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 72, 424-430 (1997).